Compare Agilent Technologies Inc (A) vs Barclays PLC (BCS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Barclays PLC — how do they compare? Agilent Technologies Inc trades at $128.44 (market cap $37.04B), while Barclays PLC trades at $26.68 (market cap $91.89B). The key difference: Barclays PLC is far larger — about 2.5× Agilent Technologies Inc's market cap, and Barclays PLC pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| A | BCS | |
|---|---|---|
Market Cap | $37.04B | $91.89B |
Sector | Health | Financials |
52-Week High | $157.20 | $28.41 |
52-Week Low | $110.24 | $18.31 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Barclays PLC (BCS) trades at $27.41, down 1.3% today but near its 52-week high of $28.43. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels indicate potential overbought conditions. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.76 exceeding expectations, and maintains a healthy net income margin of 24.5%. Revenue growth has been steady, climbing to $29.14B in 2025.
The outlook remains positive given analyst consensus favoring Buy ratings (68%) and improving cash flow trends, but risks include ongoing securities litigation and sensitivity to interest rate changes. Valuation metrics like a P/E of 12.4 and P/B of 0.95 suggest potential upside if earnings momentum continues, though investors should weigh legal overhangs against fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →
